Drug Trial Radar · NCT01016015
Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma
Last checked: Nov 20, 2026Latest source record: Jul 30, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
178
Actual
Start
Nov 2009
Primary completion
Jul 2014
Study completion Jul 2014
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Nov 18, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies how well temsirolimus and cixutumumab works in treating patients with locally advanced, metastatic, or recurrent soft tissue sarcoma or bone sarcoma. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cixutumumab, can block tumor growth by blocking the ability of tumor cells to grow and spread. Giving temsirolimus with cixutumumab may be an effective treatment for soft tissue or bone sarcoma.
Conditions
- Metastatic Osteosarcoma
- Recurrent Adult Soft Tissue Sarcoma
- Recurrent Osteosarcoma
- Stage III Adult Soft Tissue Sarcoma
- Stage IV Adult Soft Tissue Sarcoma
Interventions
CixutumumabBiological
Given IV
Laboratory Biomarker AnalysisOther
Correlative studies
TemsirolimusDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival Rate, Defined as CR + PR + SD, as Assessed by RECIST CriteriaTime frame: From study entry until recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurement recorded on study), death or date of last contact, assessed at 12 weeks
Locations
24 sites in 2 countries. Site status is shown where the registry gives one.
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California
Mayo Clinic in Florida
Jacksonville, Florida
Moffitt Cancer Center
Tampa, Florida
Northwestern University
Chicago, Illinois
University of Chicago Comprehensive Cancer Center
Chicago, Illinois
Decatur Memorial Hospital
Decatur, Illinois
NorthShore University HealthSystem-Evanston Hospital
Evanston, Illinois
Memorial Medical Center
Springfield, Illinois
University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland
University of Michigan University Hospital
Ann Arbor, Michigan
University of Michigan
Ann Arbor, Michigan
Mayo Clinic
Rochester, Minnesota
Memorial Sloan-Kettering Cancer Center
New York, New York
SUNY College at Old Westbury
Old Westbury, New York
Albert Einstein College of Medicine
The Bronx, New York
Montefiore Medical Center - Moses Campus
The Bronx, New York
Carolinas Medical Center
Charlotte, North Carolina
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
M D Anderson Cancer Center
Houston, Texas
Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia
Cross Cancer Institute
Edmonton, Alberta, Canada
University Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.